Sigilon Therapeutics, Inc.
SGTXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821323
Sigilon Therapeutics, Inc. was delisted in 2023; its insiders filed their last Form 4 on Aug 15, 2023; 16 institutions reported holding it in 13F filings for Q2 2023, worth $26.6M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Sigilon Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Sigilon Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Afeyan Noubar | 10% Owner | 0Indirect | Aug 15, 2023 | 0 |
| Flagship Pioneering, LLC | 10% Owner | 0Indirect | Aug 15, 2023 | 0 |
| Flagship Ventures Fund V, L.P. | 10% Owner | 0Indirect | Aug 15, 2023 | 0 |
| Flagship Ventures Fund V General Partner LLC | 10% Owner | 0Indirect | Aug 15, 2023 | 0 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | 10% Owner | 0Indirect | Aug 15, 2023 | 0 |
| Flagship Pioneering Special Opportunities Fund II General Partner LLC | 10% Owner | 0Indirect | Aug 15, 2023 | 0 |
| Eli Lilly & Co | 10% Owner | 100 | Aug 14, 2023 | 0 |
| Shenandoah Acquisition Corp | 10% Owner | 100 | Aug 14, 2023 | 0 |
| Oesterle Stephen N. | Director | – | Aug 11, 2023 | 0 |
| Ruffolo Robert R | Director | 0 | Aug 11, 2023 | 0 |
| Cole Douglas G. | Director | – | Aug 11, 2023 | 0 |
| Cox John | Director | 0 | Aug 11, 2023 | 0 |
| Vivaldi Coelho Rogerio | PRESIDENT AND CEO | 0 | Aug 11, 2023 | 0 |
| Shaff Eric D. | Director | – | Aug 11, 2023 | 0 |
| Patel Kavita | Director | – | Aug 11, 2023 | 0 |
| Kowalsky Matthew Paul | CHIEF OF STAFF AND CLO | 0 | Aug 11, 2023 | 0 |
| Ashton-Rickardt Philip | CHIEF SCIENTIFIC OFFICER | – | Aug 11, 2023 | 0 |
| Pontes Josias | CHIEF FINANCIAL OFFICER | 0 | Aug 11, 2023 | 0 |
| Yuan Qing Sarah | CTOO | 0 | Aug 11, 2023 | 0 |
| Story Brooke | Director | – | May 27, 2022 | 0 |
| Orfali May | CHIEF MEDICAL OFFICER | – | Feb 22, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2023 (view filing)4:30 PM ET | Aug 11 | 3 days | Eli Lilly & Co and 1 other10% Owner | PPurchase | +1.72M | $14.92 | +$25.6M | New position100 after | |
| Jul 2, 2021 (view filing) | Jul 1 | 1 day | Ruffolo Robert RDirector | SSale | −6.75K | $10.36 | −$69.9K | −100.0%0 after |